Drug Trial News

RSS

Experimental drug lowers PSA levels

A new multi-center study shows that an experimental drug lowers prostate specific antigen (PSA) levels – a marker for tumor growth – in men with advanced prostate cancer for whom traditional treatment options have failed.

9 Apr 2009

New therapy for metastatic prostate cancer shows promise

A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs.

8 Apr 2009

Trial of new biologic agent to treat psoriatic arthritis

Psoriatic arthritis affects about 11 percent of patients with psoriasis.

8 Apr 2009

Intercell starts trial for Streptococcus pneumoniae vaccine candidate

Intercell AG has announced that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.

8 Apr 2009

Experimental vaccine shows promise for the treatment of early lung cancer

An experimental vaccine that triggers the patient's immune system to identify and attack specific tumor cells is showing new promise for the treatment of early lung cancer.

6 Apr 2009

Celsion announces promising trial results for ThermoDox in breast cancer

Celsion Corporation has announced that promising Phase I clinical results evaluating ThermoDox for the treatment of recurrent chest wall (RCW) breast cancer were presented by Duke University investigators on Sunday, April 5 at the 2009 Annual Meeting of the Society for Thermal Medicine (STM) in Tucson, Arizona.

6 Apr 2009

Avastin safe and effective at delaying tumor progression

The use of Avastin alone to treat a subgroup of recurrent Grade 3 brain tumors showed it was safe and effective at delaying tumor progression, according to a retrospective study of 22 patients conducted by a researcher at the Seattle Cancer Care Alliance.

6 Apr 2009

Is telmisartan effective in treating non-alcoholic steatohepatitis?

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are well-recognized causes of progressive liver disease leading to cirrhosis and hepatocellular carcinoma.

2 Apr 2009

Bionovo announces publication of positive phase 2 trial results for Menerba

Bionovo, Inc. has announced the online publication of a peer-reviewed article in the journal, Menopause, reporting Menerba(TM) (formerly MF101) is well tolerated, safe and effective for the treatment of vasomotor symptoms (hot flashes and night sweats) associated with menopause.

2 Apr 2009

Aerovance starts phase IIb clinical trial with Aerovant for uncontrolled asthma

Aerovance Inc. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to initiate Aerovance's Phase IIb clinical trial, AeroTrial, of inhaled dry powder Aerovant in patients with uncontrolled asthma.

2 Apr 2009

Sorafenib may help patients suffering from advanced portal hypertension

In a new study, a therapeutic agent called sorafenib dramatically improved the condition of rats with portal hypertension.

1 Apr 2009

Pharmaxis reaches milestone in cystic fibrosis trial

Pharmaxis has announced completion of the first component of its Phase III international trial assessing the effectiveness of Bronchitol in people with cystic fibrosis.

1 Apr 2009

ImQuest presents data on the anti-hepatitis B virus activity of Pyrimidinediones

ImQuest Life Sciences today presented important new results on the continued development of the pyrimidinedione small molecules as antiviral agents at the 13th International Symposium on Viral Hepatitis and Liver Disease meeting held last week in Washington D.C.

31 Mar 2009

New smoking cessation drug varenicline tartrate shows promise in trials

Research has shown that varenicline tartrate - a novel new drug specifically developed for smoking cessation - allows smokers to abstain from cigarettes significantly longer and more effectively than smokers using a placebo.

31 Mar 2009

SARcode announces results of phase 1 trial of SAR 1118 ophthalmic solution in healthy adult subjects

SARcode Corporation announced today the results of its Phase 1 randomized, double-masked, placebo-controlled trial of the safety, tolerability, and pharmacokinetics of single- and multiple-escalating doses of SAR 1118 Ophthalmic Solution in healthy volunteers.

30 Mar 2009

Corthera's Relaxin in acute heart failure shows promising results

Corthera Inc. has announced that results from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, placebo-controlled international study, demonstrated promising efficacy and safety for relaxin, the company's investigational drug for treatment of acute heart failure (AHF).

30 Mar 2009

Nile Therapeutics update on phase II CD-NP trial for acute heart failure

Nile Therapeutics, Inc. has announced that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile submitted to the U.S. Food and Drug Administration (FDA) to support the initiation of the Company's Phase IIb clinical trial with CD-NP for the treatment of acute heart failure, the FDA has placed CD-NP on clinical hold.

30 Mar 2009

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

Lantheus Medical Imaging, Inc has announced new data regarding the use of DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension.

29 Mar 2009

NTRILIPIX (fenofibric acid) in combo with Rosuvastatin calcium shows improvement on key lipids for cholesterol management

Data from a new study showed that Abbott's TRILIPIX (fenofibric acid) delayed-release capsules in combination with rosuvastatin calcium met all of the study's primary endpoints.

29 Mar 2009

Medgenics’ phase I/II clinical trial shows EPODURE continuous anemia treatment lasting 5 months in kidney disease patients

Medgenics has announced that the latest, encouraging results of the Company's ongoing EPODURE Biopump Phase I/II Clinical Trial were presented at the 45th Conference of the Israeli Society of Nephrology and Hypertension, in Israel on March 27, 2009.

29 Mar 2009